Table 1.

Baseline characteristics of the subjects in Corogene, SPUM-ACS and BECAC studies

Characteristic	COROGENE		SPUM-ACS		BECAC
	Cases	Controls	Cases	Controls	Cases	Controls
No of subjects	80	80	51	1586	81	1506
Gender
Male, n (%)	60 (75%)	60 (75%)	42 (82%)	1223 (77%)	55 (68%)	889 (59%)
Age (years)	70.2 (62.6–77.1)	70 (63.4–76.9)	77.1 (69–83)	62.8 (53.9–72.9)	71 (64–78)	61 (54–70)
Body mass index	27.5 (23.6–30.9)	26 (24.1–29.5)	25.1 (23.1–28.3)	26.6 (24.3–29.4)	24 (22–28)	26 (23–28)
Time to death/follow-up time (days)	528 (134–739)	1955 (1669–2173)	25 (7–216)	365 (359–365)	626 (196–1332)	1720 (1368–2111)
Creatinine (µmol/L)	98 (84–134)	79 (69–90)	100 (79–134)	75 (65–88)	98 (87–115)	87 (79–97)
Current smoker
Yes, n (%)	37 (46%)	37 (46%)	16 (31%)	663 (42%)	29 (36%)	355 (24%)
No, n (%)	43 (54%)	43 (54%)	33 (65%)	897 (57%)	50 (62%)	1146 (76%)
NA			2 (4%)	26 (2%)	2 (2%)	5 (0%)
Diabetes
Yes, n (%)	32 (40%)	32 (40%)	11 (22%)	266 (17%)	16 (20%)	159 (11%)
No, n (%)	48 (60%)	48 (60%)	40 (78%)	1320 (83%)	64 (79%)	1333 (89%)
NA					1 (1%)	14 (1%)
Hypertension
Yes, n (%)	60 (75%)	60 (75%)	36 (71%)	912 (58%)	55 (68%)	674 (45%)
No, n (%)	20 (25%)	20 (25%)	15 (29%)	674 (42%)	26 (32%)	832 (55%)
Lipid-lowering treatment
Yes, n (%)	61 (76%)	61 (76%)	14 (27%)	432 (27%)	61 (75%)	933 (62%)
No, n (%)	19 (24%)	19 (24%)	34 (67%)	1146 (72%)	20 (25%)	573 (38%)
NA			3 (6%)
Previous AMI
Yes, n (%)	67 (84%)	0 (0%)	8 (16%)	210 (13%)	54 (67%)	482 (32%)
No, n (%)	13 (16%)	80 (100%)	43 (84%)	1374 (87%)	27 (33%)	1024 (68%)
NA				2 (0%)
Previous stroke
Yes, n (%)	17 (21%)	10 (12%)	2 (4%)	37 (2%)	15 (19%)	108 (7%)
No, n (%)	63 (79%)	70 (88%)	49 (96%)	1549 (98%)	66 (81%)	1398 (93%)